Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.69 |
| ▸ | FLT3 | P36888 | 3/20 | 0.69 |
| ▸ | FLT4 | P35916 | 2/20 | 0.69 |
| ▸ | MET | P08581 | 7/20 | 0.68 |
| ▸ | KDR | P35968 | 7/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.64 |
| ▸ | KIT | P10721 | 3/20 | 0.64 |
| ▸ | RET | P07949 | 1/20 | 0.62 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.62 |
| ▸ | AXL | P30530 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174778 | 0.90 | CSF1R (0.60) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL1877233 | 0.90 | PDGFRA (0.70) | METKDRCYP3A4CYP2D6PDGFRA | |
| SCHEMBL31324673 | 0.86 | MET (0.85) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL21301531 | 0.86 | MET (0.85) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL22104148 | 0.84 | PDGFRA (0.74) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL22972326 | 0.84 | MET (0.72) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL2174161 | 0.84 | MET (0.69) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL22104195 | 0.83 | MET (0.77) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL2174310 | 0.83 | MET (0.68) | CSF1RPDGFRBFLT3FLT4MET | |
| SCHEMBL22104152 | 0.82 | PDGFRA (0.77) | CSF1RPDGFRBFLT3FLT4MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | CSF1R 818/4885PDGFRB 2155/4885FLT3 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.